You are here: Industry Insights > Bi

News List

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China PharmaSources
May 16, 2025
InnoCare Pharma announced today that the first patient has been dosed in the Phase II/III clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment patients with non-segmental vitiligo in China.
Taking Over the "King of Medicine"? Chinese Enterprises Lead the Development of PD-(L)1/VEGF Bispecific Antibody Antitumor Drug Kevin
April 28, 2025
PD-(L)1 and VEGF (vascular endothelial growth factor) bispecific antibody therapies are considered a key direction for future tumor treatments, attracting increasing global interest due to their unique mechanism of action and promising clinical data.
Another BlockBuster in HKEX18A Biotech Companies: IPO of DualityBio in Hong Kong, Introducing New Capital Engine in the ADC Field? Kevin
April 15, 2025
On April 15, DualityBio, a rising star in the ADC field, was officially listed on the HKEX, marking one of the most high-profile IPOs in recent years in Chapter 18A Biotech Companies.
The Race to Reinvent Antibiotics: Why Innovation and Access Must Go Hand in Hand Neeta Ratanghayra
April 09, 2025
Register to Download PPT and View Why Innovation and Access Must Go Hand in Hand
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for CLL/SLL Patients in China PharmaSources
March 28, 2025
InnoCare announced the first patient dosed in the Phase III trial of ICP-248 combined with orelabrutinib for CLL/SLL. It's a potential treatment, with other trials advancing.
The Global Alpha-Glucosidase Inhibitor Market: Trends and Prospects David Orchard-Webb
March 18, 2025
Alpha-glucosidase inhibitors are used for type 2 diabetes. This article analyzes their market, including growth, segments, and challenges.
Is the Practice of "Prioritizing Biologics over Small Molecule Drugs" Justified? Krebs Qin
March 14, 2025
The article compares small molecule drugs and biologics in development, cost, etc., questions biologic - preferential policies, and mentions related acts for policy correction.
Microbiome Impact on Drug Response and Personalized Medicine Nurah Ekhlaque
February 18, 2025
The gut microbiome impacts drug response and disease management. It affects drug metabolism, efficacy, and toxicity, and is crucial for personalized medicine.
InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China PharmaSources
February 18, 2025
InnoCare Pharma announced on Feb. 17, 2025 that CDE approved the Phase III trial of ICP - 248 combined with orelabrutinib for first - line CLL/SLL treatment in China.
The Role of Biosimilars Suzanne Elvidge
February 12, 2025
Biological drugs are therapeutics that are made by living organisms or are created from cells and tissues, and include therapeutic proteins and monoclonal antibodies.

Previous Page 1 2 3 4 5 6 7 ...792 Next Page